5'-deoxy-5-fluoro-N4-[(3-phenylpropyl)oxycarbonyl]cytidine | 162204-38-8

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 5'-脱氧核糖核苷
• 英文名称: 5'-deoxy-5-fluoro-N4-[(3-phenylpropyl)oxycarbonyl]cytidine
• 英文别名: 3-phenylpropyl N-[1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxopyrimidin-4-yl]carbamate
• CAS: 162204-38-8
• 化学式: C₁₉H₂₂FN₃O₆
• 分子量: 407.399
• InChiKey: HPDRJLHMPMJQMO-BNGXUDDSSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  29
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  121
• 氢给体数：
  3
• 氢受体数：
  7

文献信息

• N-Oxycarbonyl substituted 5'-deoxy-5-fluorocytidines
  申请人：F. HOFFMANN-LA ROCHE AG

  公开号：EP0602454A1

  公开（公告）日：1994-06-22

  Compounds represented by the general formula (I),    wherein R¹ is a saturated or unsaturated, straight or branched hydrocarbon radical [wherein the number of carbon atoms in the longest straight chain of this hydrocarbon radical ranges from three to seven], or a radical of the formula -(CH₂)n-Y [in which n is an integer from 0 to 4, when Y is a cyclohexyl radical, or n is an integer from 2 to 4, when Y is a lower alkoxy radical having 1 to 4 carbon atom(s) or a phenyl radical], and R² is a hydrogen atom or a radical easily hydrolyzable under physiological conditions, as well as hydrates or solvates of the compounds of the general formula (I), can be utilized in the treatment of tumors, They can be prepared by reacting a compound of formula R¹-OCOCl with a N⁴-unsubstituted 5'-deoxy-5-fluorocytidine of the above formula I, wherein R² would stand for protecting groups, and if necessary removing the protecting groups.

  通式 (I) 所代表的化合物、 其中 R¹ 是饱和或不饱和、直链或支链烃基[其中该烃基最长直链上的碳原子数为 3 至 7]，或式 -(CH₂)n-Y 的基[其中 n 为 0 至 4 的整数、当 Y 为环己基时，或当 Y 为具有 1 至 4 个碳原子的低级烷氧基或苯基时，n 为 2 至 4 的整数]，且 R² 为氢原子或在生理条件下易于水解的基、 它们可以通过将式 R¹-OCOCl 的化合物与上式 I 的 N⁴-未取代的 5'-脱氧-5-氟胞苷反应制备，其中 R² 代表保护基团，必要时去除保护基团。
• STABILIZED CHLORITE SOLUTIONS IN COMBINATION WITH FLUOROPYRIMIDINES FOR USE IN CANCER TREATMENT
  申请人：Nuvo Research AG

  公开号：EP2428213A1

  公开（公告）日：2012-03-14

  Pharmaceutical compositions for treating neoplastic disorders and uses thereof are provided. Said pharmaceutical compositions comprise stabilised chlorite solutions (eg, WFIO) and a fluoropyrimidine, 5-FU, or a 5-FU prodrug (eg, capecitabine, doxifluridine, UFT, S-1, or BOF-A2). The use of the above stabilised chlorite solution in combination with a fluoropyrimidine dramatically improves the quality of life index (QOL) of a patent undergoing cancer chemotherapy. Cancers that can be treated include cancers of the pancreas, gastrointestinal, head, neck and breast.

  提供了治疗肿瘤性疾病的药物组合物及其用途。所述药物组合物包括稳定的亚氯酸盐溶液（如 WFIO）和氟嘧啶、5-FU 或 5-FU 原药（如卡培他滨、多西氟脲、UFT、S-1 或 BOF-A2）。将上述稳定的亚氯酸盐溶液与氟嘧啶类药物结合使用，可显著提高接受癌症化疗的患者的生活质量指数（QOL）。可治疗的癌症包括胰腺癌、胃肠癌、头颈癌和乳腺癌。